Exscientia

Exscientia is a pharmaceutical technology company that automates drug design. The company is a drug discovery company that generates data before through the analytical power of artificial intelligence.

Exscientia has developed algorithms that have reduced the time for drug discovery and development by 70%. With their help, it was possible to create drugs for the treatment of oncological, immune and psychiatric diseases.

Now there are more than 25 drugs in the development of Exscientia. The most successful have gone from identifying a drug target to choosing a candidate for a drug in less than 1.5 years. When using conventional technologies, this process takes 4.5 years.

In September 2021, Exscientia received a $35 million investment from the Bill and Melinda Gates Foundation to develop a drug against COVID-19, influenza and other viruses that could cause a new pandemic.

Timeline

April 27, 2021

Exscientia raises $225,000,000 Series D funding round led by SoftBank Vision Fund 2.

April 27, 2021

Exscientia raises a $525,000,000 series D round from Bristol-Myers Squibb, Casdin Capital, Farallon Capital Management, GT Healthcare Capital Partners, Laurion Capital, Marshall Wace, Novo Holdings and Pivotal bioVenture Partners.

March 4, 2021

Exscientia raises a $100,000,000 series C round.

March 2021

Exscientia raises a $40,000,000 series C round from BlackRock Innovation Capital, Bristol-Myers Squibb, Evotec, GT Healthcare Capital Partners and Novo Holdings.

December 2020

Exscientia raises a $4,200,000 grant from Bill & Melinda Gates Foundation.

May 2020

Exscientia raises a $60,000,000 series C round from Bristol-Myers Squibb, Evotec, GT Healthcare Capital Partners and Novo Holdings.

January 2019

Exscientia raises a $26,000,000 series B round from Celgene, Evotec and GT Healthcare Capital Partners.

September 2017

Exscientia raises a $18,000,000 series A round from Evotec.

2012

Exscientia was founded by Andrew Hopkins.

Funding Rounds

Patents

Further Resources

Title

Author

Link

Type

Date

https://investors.exscientia.ai/press-releases/press-release-details/2021/Exscientia-acquires-personalised-medicine-AI-pioneer-A

News

Title

Author

Date

Publisher

Description

Welsh scientist makes potential $539m fortune from biotech flotation in US

Julia Kollewe

October 1, 2021

the Guardian

Value of Andrew Hopkins' Exscientia firm reaches market value of $2.9bn in Nasdaq IPO

AI drug hunter Exscientia plans to go public with Nasdaq IPO

Conor Hale

September 13, 2021

FierceBiotech

The U.K.-based AI developer confidentially filed for a $100 million IPO in late June, though the pricing terms could climb higher.

Exscientia, Gates Foundation put up $35M each to prepare antivirals for next global pandemic threat

Kyle LaHucik

September 7, 2021

FierceBiotech

With the COVID-19 pandemic showing no signs of ending anytime soon and a White House ready to funnel billions into preparing for future infectious disease outbreaks, the Bill & Melinda Gates Foundation is investing $35 million in Exscientia for just that.

Bristol Myers' $1.2B discovery pact with Exscientia strikes gold as first drug candidate selected

Kyle LaHucik

August 18, 2021

FierceBiotech

Exscientia has already found a drug candidate in its $1.2 billion partnership with Bristol Myers Squibb. The Big Pharma will pay the AI-powered drug miner $20 million for the option fee just three months after expanding their collaboration, which included a $50 million upfront payment.

EQRx puts Exscientia's AI on drug discovery duty to develop low-cost cancer drugs

Andrea Park

June 23, 2021

FierceBiotech

What do you get when you cross an artificial-intelligence-powered platform for drug discovery with a corporate mission to develop a pipeline of cancer drugs with radically low prices? Exscientia and EQRx are determined to find out, with the help of a newly formed strategic collaboration.